Lung cancer is the leading cause of cancer-related deaths worldwide. Bone is a common metastatic site of lung cancer, about 50% of bone metastatic patients will experience skeletal related events (SREs). SREs not only seri-ously impact the quality of life of patients, but also shorten their survival time. The treatment of bone metastasis requires multi-disciplinary therapy (MDT) and development of individualized treatment plan. In order to stan-dardize the diagnosis and treatment of bone metastasis in lung cancer, the expert group of the MDT Committee of the Chinese Medical Doctor Association has developed the expert consensus on the diagnosis and treatment of lung cancer bone metastasis.
第一作者单位:[1]Chinese Acad Med Sci, Natl Clin Res Ctr Canc,Peking Union Med Coll, CAMS Key Lab Translat Res Lung Canc,Canc Hosp, State Key Lab Mol Oncol,Dept Med Oncol,Natl Canc, Beijing, Peoples R China[2]Shanxi Med Univ, Chinese Acad Med Sci, Shanxi Prov Canc Hosp, Dept Resp Med,Shanxi Hosp,Canc Hosp, Taiyuan, Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Duan Jianchun,Fang Wenfeng,Xu Hairong,et al.Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)[J].JOURNAL OF THE NATIONAL CANCER CENTER.2023,3(4):256-265.doi:10.1016/j.jncc.2023.08.004.
APA:
Duan, Jianchun,Fang, Wenfeng,Xu, Hairong,Wang, Jinliang,Chen, Yuan...&Wang, Jie.(2023).Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition).JOURNAL OF THE NATIONAL CANCER CENTER,3,(4)
MLA:
Duan, Jianchun,et al."Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)".JOURNAL OF THE NATIONAL CANCER CENTER 3..4(2023):256-265